Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129226908303360 |
|---|---|
| author | Mónica Bolufer Mónica Bolufer Jordi Soler Jordi Soler María Molina María Molina Omar Taco Omar Taco Anna Vila Anna Vila Manuel Macía Manuel Macía |
| author_facet | Mónica Bolufer Mónica Bolufer Jordi Soler Jordi Soler María Molina María Molina Omar Taco Omar Taco Anna Vila Anna Vila Manuel Macía Manuel Macía |
| author_sort | Mónica Bolufer |
| collection | DOAJ |
| description | Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to maintain the patient in a delicate immunologic balance in which, while antitumor therapy defeats cancer the graft is safely protected from rejection. Recent clinical trials with ICPI have included kidney transplant recipients (KTRs) and the results advocate for a paradigm shift in the management of basal immunosuppression. This suggests that downward adjustments should be avoided or, even better, that this adjustment should be “dynamic.” This review summarizes the latest scientific evidence available in renal transplantation under ICPI treatment: case series, prospective studies, histopathologic diagnosis, immunosuppression regimens and new biomarkers. This article will provide the latest information in on this specific field, allowing nephrologists to gain valuable knowledge and to be aware of new approaches to immunosuppression management in oncological kidney transplant patients. |
| format | Article |
| id | doaj-art-de7029bbf2fc42a2bc8648dd849f2cd7 |
| institution | OA Journals |
| issn | 1432-2277 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Transplant International |
| spelling | doaj-art-de7029bbf2fc42a2bc8648dd849f2cd72025-08-20T02:33:04ZengFrontiers Media S.A.Transplant International1432-22772024-11-013710.3389/ti.2024.1320413204Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and BenefitsMónica Bolufer0Mónica Bolufer1Jordi Soler2Jordi Soler3María Molina4María Molina5Omar Taco6Omar Taco7Anna Vila8Anna Vila9Manuel Macía10Manuel Macía11Department of Nephrology, Hospital Universitario Germans Trias i Pujol, Barcelona, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Badalona, SpainDepartment of Nephrology, Hospital Universitario Germans Trias i Pujol, Barcelona, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Badalona, SpainDepartment of Nephrology, Hospital Universitario Germans Trias i Pujol, Barcelona, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Badalona, SpainDepartment of Nephrology, Hospital Universitario Germans Trias i Pujol, Barcelona, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Badalona, SpainDepartment of Nephrology, Hospital Universitario Germans Trias i Pujol, Barcelona, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Badalona, SpainDepartment of Nephrology, Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, SpainRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) 2024, Santa Cruz de Tenerife, SpainCancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to maintain the patient in a delicate immunologic balance in which, while antitumor therapy defeats cancer the graft is safely protected from rejection. Recent clinical trials with ICPI have included kidney transplant recipients (KTRs) and the results advocate for a paradigm shift in the management of basal immunosuppression. This suggests that downward adjustments should be avoided or, even better, that this adjustment should be “dynamic.” This review summarizes the latest scientific evidence available in renal transplantation under ICPI treatment: case series, prospective studies, histopathologic diagnosis, immunosuppression regimens and new biomarkers. This article will provide the latest information in on this specific field, allowing nephrologists to gain valuable knowledge and to be aware of new approaches to immunosuppression management in oncological kidney transplant patients.https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/fullkidney transplantcancercheckpoint inhibitorsimmunotherapyimmunosuppresion |
| spellingShingle | Mónica Bolufer Mónica Bolufer Jordi Soler Jordi Soler María Molina María Molina Omar Taco Omar Taco Anna Vila Anna Vila Manuel Macía Manuel Macía Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits Transplant International kidney transplant cancer checkpoint inhibitors immunotherapy immunosuppresion |
| title | Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits |
| title_full | Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits |
| title_fullStr | Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits |
| title_full_unstemmed | Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits |
| title_short | Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits |
| title_sort | immunotherapy for cancer in kidney transplant patients a difficult balance between risks and benefits |
| topic | kidney transplant cancer checkpoint inhibitors immunotherapy immunosuppresion |
| url | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |
| work_keys_str_mv | AT monicabolufer immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT monicabolufer immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT jordisoler immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT jordisoler immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT mariamolina immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT mariamolina immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT omartaco immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT omartaco immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT annavila immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT annavila immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT manuelmacia immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits AT manuelmacia immunotherapyforcancerinkidneytransplantpatientsadifficultbalancebetweenrisksandbenefits |